Glycan targeting nanoparticle for photodynamic immunotherapy of melanomaopen access
- Authors
- Choi, Yonghyun; Son, Wooic; Han, Youngpin; Chae, Jayoung; Yang, Chul-Su; Choi, Jonghoon
- Issue Date
- May-2023
- Publisher
- Elsevier BV
- Keywords
- Immunotherapy; Macrophages; Phagocytosis; Lectin; Melanoma cancer; Photothermal nanoparticles; Immune checkpoint; Glycan
- Citation
- Acta Pharmaceutica Sinica B, v.13, no.5, pp.1903 - 1918
- Indexed
- SCIE
SCOPUS
- Journal Title
- Acta Pharmaceutica Sinica B
- Volume
- 13
- Number
- 5
- Start Page
- 1903
- End Page
- 1918
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/188139
- DOI
- 10.1016/j.apsb.2022.08.009
- ISSN
- 2211-3835
- Abstract
- Interaction between tumour cells and macrophages enables cancer cells to evade immune detection and clearance by interfering with macrophage phagocytosis. The anti-phagocytic signals regu-lated by anti-phagocytic proteins are termed "don't eat me" signals; these signals include sialic acid -binding immunoglobulin-type lectin-10 (Siglec-10) and the recently revealed CD24 immune checkpoint (ICP). In this study, we demonstrate that targeting a specific glycan on CD24 exhibits the potential to inhibit ICP. Sambucus nigra agglutinin (SNA), a sialic acid-binding lectin, was employed to block CD24 and to enhance phagocytosis in melanoma tumours. In addition, we prepared SNA-conjugated hol-low gold-iron oxide nanoparticles for photothermal therapy of tumours. Our findings show that the com-bination treatment of SNA-conjugated photothermal nanoparticles and near-infrared exposure successfully augments tumour cell phagocytosis both in vitro and in vivo models.(c) 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
- Files in This Item
-
Go to Link
- Appears in
Collections - ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.